ClinicalTrials.Veeva

Menu

CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Enrolling

Conditions

Non-small Cell Lung Cancer

Treatments

Biological: Serum and plasma samples

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. This would represent a rational to develop personalized follow-up and prevention strategies

Enrollment

250 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer
  • age over 18 years
  • patient naïve of any oncology treatment (excluding surgery alone) within the past 5 years
  • patient who signed the informed consent by the study protocol

Exclusion criteria were:

  • any ongoing treatment for cancer
  • any history of cancer within 5 years before the diagnosis of lung cancer
  • any psychological, sociological or geographical conditions that would not allow the study follow-up

Trial design

250 participants in 1 patient group

Patients with a non-small cell lung cancer
Description:
Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).
Treatment:
Biological: Serum and plasma samples

Trial contacts and locations

1

Loading...

Central trial contact

Cyrille Confavreux; Nicolas Girard

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems